Journal ArticleDOI
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Reads0
Chats0
TLDR
Evidence-based guidelines for the staging and treatment of SCLC are provided and the use of PET scanning is likely to improve the accuracy of staging.About:
This article is published in Chest.The article was published on 2013-05-01. It has received 304 citations till now. The article focuses on the topics: Cancer staging & Prophylactic cranial irradiation.read more
Citations
More filters
Journal ArticleDOI
Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gerard A. Silvestri,Anne V. Gonzalez,Michael A. Jantz,Mitchell L. Margolis,Michael K. Gould,Lynn T. Tanoue,Loren J. Harris,Frank C. Detterbeck +7 more
TL;DR: It is demonstrated that PET scanning is more accurate than CT scanning, but tissue biopsy is still required to confirm PET scan findings, and evidence suggests that more complete staging improves patient outcomes.
Journal ArticleDOI
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman,Harm van Tinteren,J. Praag,J. Knegjens,Sherif Y. El Sharouni,Matthew Hatton,Astrid Keijser,Corinne Faivre-Finn,Suresh Senan +8 more
TL;DR: Thoracic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patients with extensive stage small-cell lung cancer who respond to chemotherapy.
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Patent
Heterocyclic compounds and uses thereof
Alfredo C. Castro,Catherine A. Evans,Somarajannair Janardanannair,Andre Lescarbeau,Tao Liu,Daniel A. Snyder,Martin R. Tremblay,Pingda Ren,Yi Liu,Liansheng Li,Katrina Chan +10 more
TL;DR: In this article, compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activation, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activations are described.
Journal ArticleDOI
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
Charles M. Rudin,Nofisat Ismaila,Christine L. Hann,Narinder K. Malhotra,Benjamin Movsas,Kim Norris,M. Catherine Pietanza,Suresh S. Ramalingam,Andrew T. Turrisi,Giuseppe Giaccone +9 more
TL;DR: ASO endorses the ACCP guideline on the treatment of SCLC, with the addition of qualifying statements, determining that the recommendations are clear, thorough, and based on current scientific evidence.
References
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw,John Crowley,Kari Chansky,Dorothy J. Giroux,Patti A. Groome,Ramón Rami-Porta,Pieter E. Postmus,Valerie W. Rusch,Leslie H. Sobin +8 more
TL;DR: Suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor.
Journal ArticleDOI
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
Anne Auperin,Rodrigo Arriagada,J.P. Pignon,Le Péchoux C,A. Gregor,Richard Stephens,P. E.G. Kristjansen,B. E. Johnson,Hiroshi Ueoka,Henry N. Wagner,Joseph Aisner +10 more
TL;DR: Prophylactic cranial irradiation improves both overall survival and disease-free survival among patients with small-cell lung cancer in complete remission and identifies a trend toward a decrease in the risk of brain metastasis with earlier administration of cranials irradiation after the initiation of induction chemotherapy.
Journal ArticleDOI
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
Andrew T. Turrisi,KyungMann Kim,Ronald Blum,William T. Sause,Robert B. Livingston,Ritsuko Komaki,Henry N. Wagner,Seena C. Aisner,David H. Johnson +8 more
TL;DR: Four cycles of cisplatin plus etoposide and a course of radiotherapy beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results.
Journal ArticleDOI
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Karen K. Fu,Thomas F. Pajak,Andy Trotti,Christopher U. Jones,Sharon A. Spencer,Theodore L. Phillips,Adam S. Garden,John A. Ridge,Jay S. Cooper,K. Kian Ang +9 more
TL;DR: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer.
Journal ArticleDOI
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
Kazumasa Noda,Yutaka Nishiwaki,Masaaki Kawahara,Shunichi Negoro,Takahiko Sugiura,A. Yokoyama,Masahiro Fukuoka,K. Mori,Koshiro Watanabe,Tomohide Tamura,Seiichiro Yamamoto,Nagahiro Saijo +11 more
TL;DR: Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.